Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLoans and Notes ReceivablesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Gyre Therapeutics (GYRE) Leases (2019 - 2025)

Gyre Therapeutics (GYRE) has disclosed Leases for 6 consecutive years, with $1.8 million as the latest value for Q4 2024.

  • On a quarterly basis, Leases rose 268.1% to $1.8 million in Q4 2024 year-over-year; TTM through Dec 2024 was $1.8 million, a 268.1% increase, with the full-year FY2024 number at $1.8 million, up 268.1% from a year prior.
  • Leases was $1.8 million for Q4 2024 at Gyre Therapeutics, down from $2.0 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $3.1 million in Q2 2021 to a low of $17000.0 in Q1 2023.
  • A 5-year average of $1.6 million and a median of $1.8 million in 2020 define the central range for Leases.
  • Peak YoY movement for Leases: tumbled 99.24% in 2023, then surged 2252.94% in 2024.
  • Gyre Therapeutics' Leases stood at $1.8 million in 2020, then surged by 49.78% to $2.7 million in 2021, then tumbled by 75.73% to $666000.0 in 2022, then dropped by 26.58% to $489000.0 in 2023, then soared by 268.1% to $1.8 million in 2024.
  • Per Business Quant, the three most recent readings for GYRE's Leases are $1.8 million (Q4 2024), $2.0 million (Q3 2024), and $2.1 million (Q2 2024).